vs
Side-by-side financial comparison of ADC Therapeutics SA (ADCT) and Cue Biopharma, Inc. (CUE). Click either name above to swap in a different company.
ADC Therapeutics SA is the larger business by last-quarter revenue ($23.1M vs $21.9M, roughly 1.1× Cue Biopharma, Inc.). On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 36.4%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 13.7%).
ADC Telecommunications, Inc. was a communications company in Eden Prairie, Minnesota, a southwest suburb of Minneapolis. It was acquired by TE Connectivity in December 2010 and ceased to exist as a separate entity. ADC products were sold by CommScope after it acquired the Broadband Network Solutions business unit from TE Connectivity in August 2015.
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
ADCT vs CUE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.1M | $21.9M |
| Net Profit | — | $1.6M |
| Gross Margin | — | — |
| Operating Margin | -77.7% | 9.0% |
| Net Margin | — | 7.2% |
| Revenue YoY | 36.4% | 1292.3% |
| Net Profit YoY | — | 116.7% |
| EPS (diluted) | $0.04 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.1M | $21.9M | ||
| Q3 25 | $15.8M | $2.1M | ||
| Q2 25 | $18.1M | $3.0M | ||
| Q1 25 | $17.4M | $421.0K | ||
| Q4 24 | $16.9M | $1.6M | ||
| Q3 24 | $18.0M | $3.3M | ||
| Q2 24 | $17.0M | $2.7M | ||
| Q1 24 | $17.8M | $1.7M |
| Q4 25 | — | $1.6M | ||
| Q3 25 | $-41.0M | $-7.4M | ||
| Q2 25 | $-56.6M | $-8.5M | ||
| Q1 25 | $-38.6M | $-12.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-44.0M | $-8.7M | ||
| Q2 24 | $-36.5M | $-10.2M | ||
| Q1 24 | $-46.6M | $-12.3M |
| Q4 25 | -77.7% | 9.0% | ||
| Q3 25 | -196.6% | -353.4% | ||
| Q2 25 | -244.1% | -292.3% | ||
| Q1 25 | -163.5% | -2921.4% | ||
| Q4 24 | -191.8% | — | ||
| Q3 24 | -197.4% | -264.2% | ||
| Q2 24 | -170.5% | -390.6% | ||
| Q1 24 | -188.3% | -737.8% |
| Q4 25 | — | 7.2% | ||
| Q3 25 | -260.1% | -346.6% | ||
| Q2 25 | -313.2% | -287.1% | ||
| Q1 25 | -221.8% | -2911.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | -244.1% | -259.6% | ||
| Q2 24 | -214.6% | -382.7% | ||
| Q1 24 | -261.1% | -719.1% |
| Q4 25 | $0.04 | $0.05 | ||
| Q3 25 | $-0.30 | $-0.07 | ||
| Q2 25 | $-0.50 | $-0.09 | ||
| Q1 25 | $-0.36 | $-0.17 | ||
| Q4 24 | $-0.26 | — | ||
| Q3 24 | $-0.42 | $-0.17 | ||
| Q2 24 | $-0.38 | $-0.20 | ||
| Q1 24 | $-0.56 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $261.3M | $27.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-185.8M | $26.4M |
| Total Assets | $323.1M | $42.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $261.3M | $27.1M | ||
| Q3 25 | $234.7M | $11.7M | ||
| Q2 25 | $264.6M | $27.5M | ||
| Q1 25 | $194.7M | $13.1M | ||
| Q4 24 | $250.9M | $22.5M | ||
| Q3 24 | $274.3M | $32.4M | ||
| Q2 24 | $300.1M | $30.0M | ||
| Q1 24 | $234.3M | $41.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $1.0M | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | — | $3.0M |
| Q4 25 | $-185.8M | $26.4M | ||
| Q3 25 | $-238.2M | $13.2M | ||
| Q2 25 | $-199.2M | $18.2M | ||
| Q1 25 | $-238.2M | $6.6M | ||
| Q4 24 | $-202.6M | $17.5M | ||
| Q3 24 | $-171.9M | $25.4M | ||
| Q2 24 | $-131.7M | $21.6M | ||
| Q1 24 | $-194.4M | $30.0M |
| Q4 25 | $323.1M | $42.2M | ||
| Q3 25 | $289.8M | $31.6M | ||
| Q2 25 | $321.6M | $40.7M | ||
| Q1 25 | $272.5M | $22.3M | ||
| Q4 24 | $322.0M | $32.2M | ||
| Q3 24 | $349.1M | $44.8M | ||
| Q2 24 | $371.8M | $42.3M | ||
| Q1 24 | $308.0M | $54.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.09× | ||
| Q1 24 | — | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-31.1M | $-1.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | -0.68× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-31.1M | $-1.1M | ||
| Q3 25 | $-29.6M | $-9.0M | ||
| Q2 25 | $-24.1M | $-3.4M | ||
| Q1 25 | $-56.3M | $-8.2M | ||
| Q4 24 | $-21.9M | $-36.3M | ||
| Q3 24 | $-25.0M | $-7.5M | ||
| Q2 24 | $-32.8M | $-10.0M | ||
| Q1 24 | $-44.1M | $-9.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-3.4M | ||
| Q1 25 | $-56.6M | $-8.3M | ||
| Q4 24 | $-21.9M | $-36.4M | ||
| Q3 24 | $-25.3M | $-7.5M | ||
| Q2 24 | $-32.9M | $-10.0M | ||
| Q1 24 | $-44.6M | $-9.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -116.5% | ||
| Q1 25 | -325.2% | -1976.7% | ||
| Q4 24 | -129.8% | -2309.3% | ||
| Q3 24 | -140.2% | -225.7% | ||
| Q2 24 | -193.0% | -376.2% | ||
| Q1 24 | -250.0% | -573.0% |
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.9% | ||
| Q1 25 | 1.5% | 35.6% | ||
| Q4 24 | 0.5% | 4.2% | ||
| Q3 24 | 1.2% | 0.0% | ||
| Q2 24 | 0.2% | 0.4% | ||
| Q1 24 | 3.0% | 3.2% |
| Q4 25 | — | -0.68× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADCT
Segment breakdown not available.
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
